Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765049 Alone or With Ezabenlimab in Advanced Solid Tumors Expressing B7-H6
NCT06091930Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 765049 in gastrointestinal cancer, lung cancer, pancreatic cancer (PC) and 3 more (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-Limiting Toxicity at 3 weeks and Objective Response Rate at 36 months. Started Feb 2024; status: terminated.
02
Drugs
BI 765049
03
Conditions
gastrointestinal cancerlung cancerpancreatic cancer (PC)colorectal cancer (CRC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT06091930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091930.